[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cellular-tumor-antigen-p53":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Cellular Tumor Antigen p53",4,3,[8,16,22,28],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05640999","Adjuvant Therapy in POLE-Mutated and p53-Wildtype\u002FNSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER",[12],"Phase 2","RECRUITING","2026-08-26T02:16:24.135291Z","2026-05-05T02:43:28.517766Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06926634","Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)",[12],"2026-08-26T02:17:22.949982Z","2026-05-05T02:35:31.706749Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT03824483","Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)",[12],"2026-08-26T02:15:09.079045Z","2026-05-05T02:43:27.422581Z",{"nct_id":29,"title":30,"phases":31,"status":33,"updated_at":34,"content_modified":35},"NCT07617363","ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS",[32],"Phase 1","NOT_YET_RECRUITING","2026-08-26T02:16:54.044282Z","2026-06-02T11:21:24.699658Z"]